Amlexanox Sales

Amlexanox Sales Market Outlook

The global Amlexanox sales market is projected to reach USD 1.2 billion by 2035, growing at a remarkable CAGR of 8.2% from 2025 to 2035. The surge in the market can be attributed to the increasing prevalence of oral and skin disorders, along with a rising demand for effective anti-inflammatory treatments. Additionally, the growing awareness among patients regarding oral hygiene and the availability of Amlexanox products in various forms have significantly contributed to market growth. Furthermore, advancements in pharmaceutical formulations and the introduction of innovative distribution channels are expected to bolster sales in emerging markets. The focus on research and development to enhance the efficacy and safety profiles of Amlexanox products is also anticipated to drive the market forward.

Growth Factor of the Market

Several factors are expected to drive the growth of the Amlexanox sales market in the coming years. Firstly, the increasing incidence of oral ulcers and related disorders among the global population is a primary growth driver, particularly in aging demographics where such conditions are more prevalent. Secondly, there is a growing trend of self-medication, with patients seeking over-the-counter solutions for common ailments, leading to a higher demand for Amlexanox formulations. Furthermore, the technological advancements in pharmaceutical manufacturing are allowing for the development of more efficient delivery methods, enhancing patient compliance and satisfaction. Additionally, as healthcare systems increasingly emphasize preventive care and early intervention, the popularity of therapeutic agents like Amlexanox that can relieve symptoms quickly will likely foster market expansion. Lastly, the growing influence of e-commerce and online pharmacies facilitates easier access to these products, further driving their sales.

Key Highlights of the Market

• The Amlexanox sales market is expected to reach USD 1.2 billion by 2035.
• Projected growth at a CAGR of 8.2% from 2025 to 2035.
• Increased prevalence of oral ulcers and inflammatory conditions driving demand.
• Technological advancements enhancing formulation efficacy and delivery methods.
• Growing popularity of online pharmacies providing easy access to consumers.

By Product Type

Oral Paste:

Oral paste is one of the most commonly used forms of Amlexanox, primarily due to its ease of application and effectiveness in treating oral lesions. This formulation allows for direct application on affected areas, providing localized relief from discomfort and promoting healing. The oral paste is particularly favored by patients suffering from oral ulcers, as it offers a protective barrier that helps to soothe irritation and reduce pain. The growing acceptance of oral pastes in both clinical and home settings is expected to fuel the segment's growth as more patients become aware of their benefits in managing oral health issues.

Oral Tablets:

The oral tablet form of Amlexanox is also significant in the market, primarily due to its convenience and dosage accuracy. Tablets are easy to ingest and are well-suited for patients who prefer systemic treatment for inflammatory conditions. This formulation provides a reliable dose of the active ingredient, ensuring consistent therapeutic effects. The rising trend of polypharmacy among patients suffering from multiple health issues further supports the demand for oral tablets, as they can be easily integrated into existing treatment regimens. Additionally, the availability of various dosages of Amlexanox tablets caters to a wide range of patient needs, enhancing their market presence.

Oral Gel:

Amlexanox oral gel represents a versatile option for patients requiring targeted treatment for oral ulcers. The gel formulation offers a soothing consistency that can adhere to mucosal surfaces, providing longer-lasting relief from symptoms compared to other forms. This property makes oral gels particularly appealing for patients with recurrent oral ulcers, ensuring that the active ingredient remains in contact with the affected area for an extended period. As awareness of the benefits of oral gels continues to grow, this segment is likely to see robust growth, driven by both consumer preferences and increasing availability in pharmacies.

Topical Cream:

Topical creams containing Amlexanox are designed for external application to treat various skin disorders and allergic reactions. The cream formulation allows for easy and precise application, ensuring that the active ingredient penetrates the affected area effectively. Topical creams are often preferred for their moisturizing effects, which can help soothe inflammation and promote healing. As skin disorders become more common due to environmental factors and lifestyle changes, the demand for such topical treatments is expected to rise, bolstering the growth of this segment in the Amlexanox sales market.

Topical Gel:

Topical gels offer a lightweight and non-greasy alternative for patients dealing with skin conditions. The gel formulation is particularly beneficial for those who experience irritation or discomfort, as it is often more easily absorbed than creams, providing quick relief. The demand for topical gels has been fueled by the growing trend of aesthetic treatments and the need for effective solutions for conditions such as psoriasis and eczema. As consumers increasingly seek products that offer both therapeutic benefits and ease of use, the segment of topical gels in the Amlexanox market is poised for significant growth in the coming years.

By Application

Oral Ulcers:

The application of Amlexanox for oral ulcers represents a significant segment of the market. Oral ulcers can cause considerable pain and discomfort, leading to difficulties in eating, drinking, and speaking. Amlexanox has been shown to be effective in reducing pain and healing these lesions, making it a popular choice among healthcare providers and patients alike. As the prevalence of oral ulcers increases due to factors such as stress, nutritional deficiencies, and certain medical conditions, the demand for products containing Amlexanox specifically targeting this application is expected to rise substantially.

Allergic Reactions:

Another vital application area for Amlexanox is in managing allergic reactions. This can include reactions to various allergens that lead to skin irritations or mucosal inflammation. The anti-inflammatory properties of Amlexanox help alleviate symptoms associated with allergic responses, providing relief to patients affected by these conditions. As awareness of allergic reactions grows and more individuals seek effective treatments, the market for Amlexanox in this application area is poised for growth, driven by both patient needs and healthcare recommendations.

Inflammatory Conditions:

Amlexanox is also prominently used in the treatment of various inflammatory conditions, where its ability to inhibit inflammation directly contributes to patient recovery. Conditions such as gingivitis and other forms of mucosal inflammation benefit from the application of Amlexanox, which acts to reduce swelling and discomfort. The rise in prevalence of inflammatory diseases due to lifestyle changes and environmental factors is anticipated to drive growth in this application segment. With healthcare systems increasingly prioritizing inflammatory condition management, products featuring Amlexanox will likely gain further traction in the market.

Skin Disorders:

Skin disorders, including eczema, psoriasis, and dermatitis, represent another critical application area for Amlexanox products. The compound's anti-inflammatory and healing properties make it suitable for treating a wide range of skin conditions, providing symptomatic relief and promoting skin regeneration. As the incidence of skin disorders continues to rise, fueled by environmental stressors and lifestyle factors, the demand for effective topical treatments such as Amlexanox is expected to increase significantly. This trend is likely to foster a competitive landscape where companies focus on developing innovative formulations to meet rising consumer expectations.

Others:

In addition to the primary applications mentioned, there are several other uses for Amlexanox that contribute to its overall market presence. These may include therapeutic applications in niche areas, where its unique properties can be leveraged to treat specific conditions not covered under broader categories. The versatility of Amlexanox means that as research continues and new applications are explored, additional opportunities for growth within the market may arise. This segment's potential will be closely monitored by stakeholders looking to capitalize on emerging trends and consumer needs.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of Amlexanox products, particularly for patients who require immediate access to medications during their hospital stays. These facilities often stock a range of formulations to cater to the diverse needs of patients suffering from oral ulcers and skin disorders. The healthcare providers in hospitals typically recommend the use of Amlexanox due to its proven efficacy, thus driving sales through this channel. As hospitals continue to prioritize effective treatment options for patients, the importance of hospital pharmacies in the Amlexanox sales market will remain significant.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for Amlexanox, offering easy access for consumers seeking over-the-counter solutions for oral and skin conditions. The convenience of retail pharmacies makes them a popular destination for patients who prefer to purchase medications without needing a prescription. This segment is particularly responsive to marketing and promotional efforts, which can influence consumer behavior and preferences. As the demand for Amlexanox products grows, retail pharmacies will continue to play a vital role in providing these treatments to the public, further enhancing their market presence.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for Amlexanox, catering to the growing trend of e-commerce in healthcare. Patients appreciate the convenience of purchasing medications online, especially for conditions that may carry stigma or embarrassment, such as oral ulcers. The ability to browse a wide selection of products and receive discreet delivery has positioned online pharmacies as a preferred choice for many consumers. As digital transformation in healthcare continues, the share of online pharmacies in the Amlexanox sales market is expected to expand, driven by consumer demand for convenience and accessibility.

Drug Stores:

Drug stores are another essential distribution channel for Amlexanox, providing a range of healthcare products, including both prescription and over-the-counter medications. These establishments often stock various formulations, allowing consumers to choose based on their specific needs and preferences. The presence of trained pharmacy personnel also enhances customer experience, as they can provide advice and guidance on the use of Amlexanox products. As drug stores continue to evolve and adapt to consumer demands, their role in the Amlexanox sales market will remain influential, contributing to overall growth.

Others:

Other distribution channels, including specialty stores and direct-to-consumer sales, provide additional avenues for the sale of Amlexanox products. Specialty stores may cater to specific demographics or health concerns, offering tailored solutions for consumers seeking targeted treatments. Meanwhile, direct-to-consumer sales enable manufacturers to engage directly with patients, fostering loyalty and brand recognition. As the market landscape evolves, these alternative distribution channels are likely to play an increasingly important role in enhancing the accessibility and availability of Amlexanox products.

By Ingredient Type

Amlexanox 5% Cream:

Amlexanox 5% cream is one of the key formulations available in the market, known for its potent therapeutic effects in treating inflammatory conditions and oral ulcers. This specific concentration allows for effective application, ensuring that the active ingredient penetrates the affected area adequately to provide relief. The cream formulation is especially sought after for its soothing properties, which help alleviate discomfort associated with skin disorders. As consumer awareness of effective topical treatments grows, the demand for Amlexanox 5% cream is expected to rise, further solidifying its position in the market.

Amlexanox 1% Oral Paste:

Amlexanox 1% oral paste is primarily utilized for the treatment of oral ulcers, providing a targeted approach to managing pain and promoting healing. This formulation is particularly favored by patients due to its easy application and fast-acting nature. The paste adheres well to mucosal surfaces, ensuring that the active ingredient remains in contact with the ulcer for an extended period, which is crucial for effective treatment. As awareness regarding the benefits of targeted oral care continues to grow, the demand for Amlexanox 1% oral paste is anticipated to see significant growth in the coming years.

Amlexanox 2% Gel:

Amlexanox 2% gel offers a lightweight option for patients looking for effective treatment for oral and skin conditions. The gel formulation is known for its quick absorption, which provides rapid relief from symptoms associated with oral ulcers and skin irritations. This formulation appeals to consumers who prefer a non-greasy option that can be easily spread on affected areas. As the market for topical treatments continues to expand, the demand for Amlexanox 2% gel is likely to grow, supported by an increasing focus on patient preferences and comfort.

Amlexanox 0.5% Tablets:

Amlexanox 0.5% tablets are an essential formulation for patients seeking systemic treatment for inflammatory conditions. This lower concentration is suitable for patients who may require a gentler approach to managing symptoms and offers flexibility in dosage. The convenience of oral tablets makes them a popular choice among consumers, especially for those who prefer not to apply topical treatments. As healthcare practices increasingly emphasize individualized treatment plans, the demand for Amlexanox 0.5% tablets is expected to remain strong, catering to a diverse patient population.

Others:

In addition to the major formulations mentioned, there are several other variations of Amlexanox products available in the market, which cater to specific patient needs or preferences. These may include combinations with other active ingredients or formulations designed for specialized applications. The versatility of Amlexanox allows for the development of innovative products that can address unique health challenges faced by consumers. As research continues to uncover the potential applications of Amlexanox, the segment of 'Others' is likely to expand, contributing to the overall growth of the market.

By Region

The regional analysis of the Amlexanox sales market reveals significant variations in demand and growth potential across different areas. North America holds a substantial share of the market, attributed to a high prevalence of oral and skin disorders, along with advanced healthcare infrastructure and strong consumer awareness of treatment options. The market in North America is projected to grow at a CAGR of 8.5%, supported by the increasing availability of Amlexanox products through various distribution channels. Meanwhile, Europe also represents a key market for Amlexanox, driven by rising healthcare expenditure and a growing focus on dermatological treatments. The demand for Amlexanox in this region is expected to remain robust as more patients seek effective solutions for managing oral and skin conditions.

In the Asia Pacific region, the Amlexanox sales market is witnessing rapid growth, projected to grow at a CAGR of 9.0% from 2025 to 2035. This growth can be attributed to increasing urbanization, rising disposable incomes, and a growing awareness of healthcare among the population. Additionally, the burgeoning pharmaceutical market in countries like India and China is expected to further boost the demand for Amlexanox products. Latin America and the Middle East & Africa are also emerging markets, where the demand for Amlexanox is expected to rise due to improving healthcare access and growing awareness about oral and skin health issues among consumers.

Opportunities

The Amlexanox sales market presents numerous opportunities for growth, particularly in emerging markets where healthcare access is improving. As countries continue to invest in their healthcare systems and enhance drug availability, there is a significant opportunity for manufacturers to expand their reach and tap into new customer bases. Furthermore, the increasing popularity of e-commerce platforms for pharmaceutical sales opens up new channels for distribution, allowing companies to connect directly with consumers and enhance brand loyalty. The rise of telemedicine and digital health solutions also presents opportunities for the promotion of Amlexanox products, particularly as patients look for convenient treatment options for common ailments.

Research and development also represent a significant opportunity for the Amlexanox market. As pharmaceutical companies continue to invest in innovative formulations that improve efficacy and patient experience, there is potential for creating new product offerings that cater to specific health concerns. Additionally, collaborations with healthcare providers to raise awareness about the benefits of Amlexanox for managing oral and skin conditions can lead to increased prescriptions and consumer adoption. The focus on preventive healthcare and self-medication is expected to foster a favorable environment for Amlexanox products, enabling sustained growth in the market.

Threats

Despite the positive outlook for the Amlexanox sales market, several threats could pose challenges to growth. One significant threat is the increasing competition from alternative treatments and generic formulations that may provide similar benefits at lower costs. As more companies enter the market with competitive pricing strategies, established brands may face pressure on their market share, potentially impacting profitability. Furthermore, regulatory challenges and stringent approval processes for new formulations can hinder innovation and slow the introduction of new products to the market. Additionally, fluctuations in raw material prices and potential supply chain disruptions could affect production costs and availability, impacting overall market dynamics.

Another considerable threat to the Amlexanox sales market is the rising awareness of side effects associated with certain treatments. As patients become more informed about potential risks, they may be less inclined to use specific medications, including those containing Amlexanox. This shift in consumer attitude could lead to a decline in sales for certain product types. Moreover, economic downturns may affect consumer spending on healthcare products, pushing patients towards lower-cost alternatives or delaying treatment. Companies in the Amlexanox market will need to address these threats proactively by enhancing their product offerings, improving patient education, and monitoring market trends closely.

Competitor Outlook

• Pfizer Inc.
• GSK (GlaxoSmithKline) plc
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Novartis AG
• Amgen Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Roche Holding AG
• AstraZeneca PLC

The competitive landscape of the Amlexanox sales market is characterized by the presence of major pharmaceutical companies that dominate the industry. These companies are engaged in continuous research and development to enhance their product offerings, ensuring that they meet the evolving needs of consumers. With a focus on innovation, these firms are exploring new formulations and delivery systems for Amlexanox, which may include combinations with other active ingredients to improve efficacy. Additionally, strategic partnerships and collaborations with healthcare providers are common practices among these competitors, as they aim to raise awareness about the benefits of Amlexanox and foster brand loyalty among healthcare professionals and patients alike.

Among the key players, Pfizer Inc. stands out for its extensive research capabilities and strong market presence. Known for its commitment to innovation, Pfizer has been actively involved in developing new Amlexanox formulations while ensuring compliance with stringent regulatory standards. Similarly, GSK plc has focused on leveraging its global reach to introduce Amlexanox products in various markets, capitalizing on the growing demand for effective treatments. Teva Pharmaceutical Industries Ltd. and Mylan N.V. are also prominent players in the generic market, offering cost-effective alternatives to brand-name products while maintaining high quality. Their competitive pricing strategies aim to capture market share in regions with price-sensitive consumers.

Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. are vital competitors in the Asian market, where they focus on expanding their portfolios with Amlexanox products tailored to local healthcare needs. Their investments in manufacturing capabilities and distribution networks enable them to serve a growing population seeking effective treatments for oral and skin conditions. Finally, companies like Novartis AG and AbbVie Inc. are also exploring opportunities to integrate Amlexanox into combination therapies, providing a more comprehensive approach to patient care. The competitive landscape will continue to evolve as companies adapt to market dynamics and prioritize consumer needs.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GSK (GlaxoSmithKline) plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Dr. Reddy's Laboratories Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Amlexanox Sales Market, By Application
    • 6.1.1 Oral Ulcers
    • 6.1.2 Allergic Reactions
    • 6.1.3 Inflammatory Conditions
    • 6.1.4 Skin Disorders
    • 6.1.5 Others
  • 6.2 Amlexanox Sales Market, By Product Type
    • 6.2.1 Oral Paste
    • 6.2.2 Oral Tablets
    • 6.2.3 Oral Gel
    • 6.2.4 Topical Cream
    • 6.2.5 Topical Gel
  • 6.3 Amlexanox Sales Market, By Ingredient Type
    • 6.3.1 Amlexanox 5% Cream
    • 6.3.2 Amlexanox 1% Oral Paste
    • 6.3.3 Amlexanox 2% Gel
    • 6.3.4 Amlexanox 0.5% Tablets
    • 6.3.5 Others
  • 6.4 Amlexanox Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Amlexanox Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Amlexanox Sales market is categorized based on

By Product Type

• Oral Paste
• Oral Tablets
• Oral Gel
• Topical Cream
• Topical Gel

By Application

• Oral Ulcers
• Allergic Reactions
• Inflammatory Conditions
• Skin Disorders
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Amlexanox 5% Cream
• Amlexanox 1% Oral Paste
• Amlexanox 2% Gel
• Amlexanox 0.5% Tablets
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• GSK (GlaxoSmithKline) plc
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Novartis AG
• Amgen Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Roche Holding AG
• AstraZeneca PLC